Sanofi records €1B+ impairment hit Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 30 July, 2026

sponsored by Medicine is a national security asset. America wins by building, not retreating. Adversary states are investing to control the biopharmaceutical capacity that national security now depends on. China already hosts 39 percent of the world's clinical trials. America cannot afford to surrender leadership of this strategic industry. But tariffs, decoupling, and blanket bans are not toughness. They are retreat. America wins by building capacity at home and with trusted allies, and by out-competing rivals instead of hiding from them. See where we stand

news J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech Sanofi records €1B+ write-off, ends work on two immunology assets Relation promises 'transformationally different success rates' in expanded AI pact with GSK Updated: FDA adcomm votes down Capricor's DMD therapy over efficacy

Jul 30 1:00 pm ET Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights sponsored by GUARDANT Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM

Associate Director / Director, Preclinial Development - Immunology Terray Therapeutics, Inc. Monrovia, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The China biotech story is moving fast. On Aug. 6, Endpoints hosts debate-style panels on how China's rise is forcing biotech to rethink innovation, live in Boston. Space is limited. Reserve your spot now.

ENDPOINTS PHARMA FTC sues Hims for sharing sensitive health information, billing practices Teva CEO says there's time to prepare for Trump's tariffs on generics NYU's Neil Vasan departs as acting chair of FDA's cancer drug advisory panel State Department releases $600M for global health group Gavi

in case you missed it 1. Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor 2. Exclusive: After learning the ropes as Recursion CEO, Chris Gibson joins VC firm Dimension Capital 3. Leqembi records best quarter since launch as Biogen raises guidance 4. News Briefing Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months 5.